People

Denis Bedoret

Denis Bedoret currently serves as Executive Director of Neuvasq Biotechnologies. He is also Director in the Boards of Ncardia, BePharBel, and previously Exothera. Prior to taking its new role at Neuvasq, Denis was Chief Executive Officer at Imcyse, a clinical-stage biopharmaceutical company committed to advancing the development of a new class of specific immunotherapies to treat auto-immune diseases. Prior to this, he was the CEO of MaSTherCell SA, Belgium and President of MaSTherCell Global Inc., U.S. Under his leadership, the Company expanded significantly growing from 60 to 260 employees and positioning as a leader in the field of CDMO’s dedicated to Cell and Gene therapies products before being acquired by Catalent. Denis also held the position of Chief Operations Officer at Quality Assistance S.A. a leading European analytical CRO where he was also a member of the Board of Directors. Before that, Denis served as engagement manager at McKinsey & Company, focusing on life science projects.